Enhanced design of inhaled therapeutics: what does the future hold? - Wikidata - wikimedia - TriplyDB

Enhanced design of inhaled therapeutics: what does the future hold?

Enhanced design of inhaled therapeutics: what does the future hold?

http://www.wikidata.org/entity/Q48209139

about

Design and development of a biorelevant simulated human lung fluid

P2860

Q57057292-A3C55C53-4C98-4512-9CF6-E6BFAE79B81A

P2860

Enhanced design of inhaled therapeutics: what does the future hold?

http://www.wikidata.org/entity/Q48209139

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Enhanced design of inhaled therapeutics: what does the future hold?

@en

Enhanced design of inhaled therapeutics: what does the future hold?

@nl

type

label

Enhanced design of inhaled therapeutics: what does the future hold?

@en

Enhanced design of inhaled therapeutics: what does the future hold?

@nl

prefLabel

Enhanced design of inhaled therapeutics: what does the future hold?

@en

Enhanced design of inhaled therapeutics: what does the future hold?

@nl

P1433

Q48209139-04E99619-FDA5-4103-B3A3-86C1C01B80CE

P1476

Q48209139-91CCE887-DB33-4F00-AC4E-9958CB6B55B2

P2093

Q48209139-D467F40C-80CA-4B13-9DCE-1ED78F01BB27

P2860

Q48209139-038EF527-A723-4223-81DD-C74CDD4730A1

Q48209139-0B127385-60AC-4E8A-A8EF-784869B2AB4C

Q48209139-0B8570E2-3E5D-4D70-9CCE-BD7A975D28AA

Q48209139-195B1733-7D1B-485B-AB61-AA55F4CC0B64

Q48209139-1F946E4F-44C2-4977-9B11-31DCA49B3E36

Q48209139-5B249F5A-197D-4651-9B9D-F46BE8C32590

Q48209139-5C0D3306-9709-421A-817F-C8FB307AA237

Q48209139-793F5723-DC36-44B9-A7F6-1EA035E2C4F5

Q48209139-8A5D0B58-B8F4-4179-95B9-308C73119F5D

Q48209139-92CF45D7-08A9-49F9-ACE2-EFD35F0312D6

P304

Q48209139-DE609717-E64D-4877-814D-9264A76AFB1A

P31

Q48209139-1ED504DC-B3F2-43E1-81F9-F6EDF02C21AC

Q48209139-b3834c80-a1f5-4485-9c87-191d4f66890d

P356

Q48209139-CC4ABA78-86C1-4607-9282-7D6252E638B2

P433

Q48209139-94ABE739-BA33-4C80-8E31-2A10639836D4

P478

Q48209139-7004BBBD-AB03-4913-962F-A2E0C8E0B495

P577

Q48209139-894936E9-B6A5-4F0F-BFB9-A82BBEB358A4

P698

Q48209139-E789076D-66AB-4270-8BBF-4EF9D4E96595

P356

P1433

Therapeutic delivery

P1476

Enhanced design of inhaled therapeutics: what does the future hold?

@en

P2093

Jeffry G Weers

http://www.w3.org/2001/XMLSchema#string

P2860

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulation

The rule of five for non-oral routes of drug delivery: ophthalmic, inhalation and transdermal

Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease.

A review of the value of innovation in inhalers for COPD and asthma.

Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

A perspective on synthetic and solid-form enablement of inhalation candidates.

Asthma phenotypes: the evolution from clinical to molecular approaches.

Inhaler competence in asthma: common errors, barriers to use and recommended solutions.

Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery.

P304

145-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/TDE-2016-0004

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26893244

http://www.w3.org/2001/XMLSchema#string